Structure of N-Me-Leu-OH
CAS No.: 3060-46-6
*Storage: {[sel_prStorage]}
*Shipping: {[sel_prShipping]}
The BI-3802 was designed by Boehringer Ingelheim and could be obtained free of charge through the Boehringer Ingelheim open innovation portal opnMe.com, associated with its negative control.
4.5
*For Research Use Only !
Change View
| Size | Price | VIP Price |
DE Stock US Stock |
Asia Stock Global Stock |
In Stock |
| {[ item.pr_size ]} |
Inquiry
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.discount_usd) ]} {[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} |
Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]} | {[ item.p_spot_brand_remark ]} 1-2 weeks {[ item.pr_usastock ]} In Stock Inquiry - | {[ item.p_spot_brand_remark ]} 1-2 weeks {[ item.pr_chinastock ]} {[ item.pr_remark ]} In Stock Inquiry - | Login - + |
Please Login or Create an Account to: See VIP prices and availability
Asia Stock: Ship in 3-5 business days
EU Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
{[ item.p_spot_brand_remark ]}
1-2weeks
Inquiry
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ item.p_spot_brand_remark ]}
1-2weeks
Inquiry
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
In Stock
- +
Please Login or Create an Account to: See VIP prices and availability
Asia Stock: Ship in 3-5 business days
EU Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Antimycobacterial Rufomycin Analogues from Streptomyces atratus Strain MJM3502
Zhou, Bin ; Shetye, Gauri ; Yu, Yang ; Santarsiero, Bernard D. ; Klein, Larry L. ; Abad-Zapatero, Cele , et al.
Abstract: This study represents a systematic chem. and biol. study of the rufomycin (RUF) class of cyclic heptapeptides, which our anti-TB drug discovery efforts have identified as potentially promising anti-TB agents that newly target the caseinolytic protein C1, ClpC1. Eight new RUF analogs, rufomycins NBZ1-NBZ8, as well as 5 known peptides were isolated and characterized from the Streptomyces atratus strain MJM3502. Advanced Marfey's and X-ray crystallog. anal. led to the assignment of the absolute configuration of the RUFs. Several isolates exhibited potent activity against both pathogens M. tuberculosis H37Rv and M. abscessus, paired with favorable selectivity (selectivity index >60), which collectively underscores the promise of the rufomycins as potential anti-TB drug leads.
Show More >
| CAS No. : | 3060-46-6 |
| Formula : | C7H15NO2 |
| M.W : | 145.20 |
| SMILES Code : | CC(C)C[C@H](NC)C(O)=O |
| MDL No. : | MFCD00065919 |
| InChI Key : | XJODGRWDFZVTKW-LURJTMIESA-N |
| Pubchem ID : | 2777993 |
| GHS Pictogram: |
|
| Signal Word: | Warning |
| Hazard Statements: | H302-H315-H319-H335 |
| Precautionary Statements: | P261-P305+P351+P338 |
| Num. heavy atoms | 10 |
| Num. arom. heavy atoms | 0 |
| Fraction Csp3 | 0.86 |
| Num. rotatable bonds | 4 |
| Num. H-bond acceptors | 3.0 |
| Num. H-bond donors | 2.0 |
| Molar Refractivity | 40.34 |
| TPSA ? Topological Polar Surface Area: Calculated from |
49.33 Ų |
| Log Po/w (iLOGP)? iLOGP: in-house physics-based method implemented from |
1.68 |
| Log Po/w (XLOGP3)? XLOGP3: Atomistic and knowledge-based method calculated by |
-1.17 |
| Log Po/w (WLOGP)? WLOGP: Atomistic method implemented from |
0.71 |
| Log Po/w (MLOGP)? MLOGP: Topological method implemented from |
-1.47 |
| Log Po/w (SILICOS-IT)? SILICOS-IT: Hybrid fragmental/topological method calculated by |
0.32 |
| Consensus Log Po/w? Consensus Log Po/w: Average of all five predictions |
0.01 |
| Log S (ESOL):? ESOL: Topological method implemented from |
0.26 |
| Solubility | 265.0 mg/ml ; 1.82 mol/l |
| Class? Solubility class: Log S scale |
Highly soluble |
| Log S (Ali)? Ali: Topological method implemented from |
0.63 |
| Solubility | 615.0 mg/ml ; 4.24 mol/l |
| Class? Solubility class: Log S scale |
Highly soluble |
| Log S (SILICOS-IT)? SILICOS-IT: Fragmental method calculated by |
-0.95 |
| Solubility | 16.4 mg/ml ; 0.113 mol/l |
| Class? Solubility class: Log S scale |
Soluble |
| GI absorption? Gatrointestinal absorption: according to the white of the BOILED-Egg |
High |
| BBB permeant? BBB permeation: according to the yolk of the BOILED-Egg |
Yes |
| P-gp substrate? P-glycoprotein substrate: SVM model built on 1033 molecules (training set) |
No |
| CYP1A2 inhibitor? Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set) |
No |
| CYP2C19 inhibitor? Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set) |
No |
| CYP2C9 inhibitor? Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set) |
No |
| CYP2D6 inhibitor? Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set) |
No |
| CYP3A4 inhibitor? Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set) |
No |
| Log Kp (skin permeation)? Skin permeation: QSPR model implemented from |
-8.02 cm/s |
| Lipinski? Lipinski (Pfizer) filter: implemented from |
0.0 |
| Ghose? Ghose filter: implemented from |
None |
| Veber? Veber (GSK) filter: implemented from |
0.0 |
| Egan? Egan (Pharmacia) filter: implemented from |
0.0 |
| Muegge? Muegge (Bayer) filter: implemented from |
1.0 |
| Bioavailability Score? Abbott Bioavailability Score: Probability of F > 10% in rat |
0.55 |
| PAINS? Pan Assay Interference Structures: implemented from |
0.0 alert |
| Brenk? Structural Alert: implemented from |
0.0 alert: heavy_metal |
| Leadlikeness? Leadlikeness: implemented from |
No; 1 violation:MW<1.0 |
| Synthetic accessibility? Synthetic accessibility score: from 1 (very easy) to 10 (very difficult) |
1.52 |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.


[ 72-18-4 ]
[ 2480-23-1 ]
[ 3060-46-6 ]

[ 72-18-4 ]
[ 2480-23-1 ]
[ 3060-46-6 ]
| Yield | Reaction Conditions | Operation in experiment |
|---|---|---|
| The following can be prepared in a similar way: (S)-Z-N-Methylglycine, (S)-Z-N-methylalanine, (S)-Z-N-methyl-S-benzylcysteine; (S)-Z-N-methylleucine, (S)-Z-N-methylmethionine, (S)-Z-N-methyl-O-benzylthreonine. | ||
| 0.85 g (46%) | methyl-L-leucine (NPC 15273) A suspension of N-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-leucine (1.67 g, 5 mmol) in toluene(100 ml) was charged with paraformaldehyde (1 g, 33.3 mmol) and 4-toluenesulfonic acid (100 mg, catalytic). The mixture was refluxed for 30 minutes in a Dean Stark apparatus for azeotropic distillation. The solution was washed with a saturated solution of sodium bicarbonate (*2), dried over magnesium sulfate and evaporated. The resulting oil in a 1:1 mixture of chloroform:trifluoroacetic acid (50 ml), at room temperature, was charged with triethylsilane (2.38 ml, 15 mmol). Stirring was continued for 22 hr. The solvents were removed in vacuum and the oil was crystallized from a mixture of ether:hexane. Recrystalyzation from EtOAc:hexane afforded 0.85 g (46%) of the product as a colorless solid, mp 101-3 C. | |
| Characterising data Physical and spectral properties of MM 45289 after drying over P2O5: FAB-MS (glycerol/thioglycerol/trifluoroacetic acid) MH+1557+-1 Molecular Weight: 1556 Molecular Formula: C73H89N10O26Cl UV (H2O) lambdamax280 nm (epsilon 6215) [alpha]D20 -118 (c = 0.97% in H2O) IR (kBr) 1660, 1590, 1500, 1070 cmmin1 1H NMR in DMSO d6 at 358K. Tetramethylsilane as internal standard. deltaH 8.45 (1H, broad s), 8.23 (1H, br d, J ca.5Hz), 7.95 (1H, br d, J ca.5Hz), 7.63 (1H, d, J 8.0Hz), 7.52 (1H, d, J 8.3Hz), 7.39 (1H, s), 7.33 (1H, br d), 7.23 (1H, d, J 8.3Hz), 7.12 (1H, s), 7.1 (1H, br d), 6.97 (1H, d, J 8.0Hz), 6.76 (1H, dd, J 8.4 and 2.0Hz), 6.68 (1H, d, J 8.4Hz), 6.45 (1H, d, J 2.0Hz), 6.33 (1H, d, J 2.0Hz), 5.68 (1H, br), 5.63 (1H, s), 5.50 (1H, d, J 7.4Hz), 5.43 (1H, s), 5.27 (2H, overlapping), 5.13 (1H, d, J ca.2Hz), 4.70 (2H, overlapping), 4.50 (1H, d, J 6Hz), 4.47 (1H, d, J 6.1), 4.33 (1H, br), 4.21 (1H, br), 4.13 (1H, dq, J 6.0 and 9.6Hz), 3.75 - 3.30 (7H, overlapping), 3.00 (1H, dd, J 7.8 and 5.8Hz) 2.88 (1H, d, J 9.6Hz), 2.86 (lH, d, J 9.6Hz), 2.58 (lH, dd, J 15.8 and 4.0Hz), 2.32 (3H, s), 2.17 (lH, dd, 15.8 and 6.8Hz), 1.90 (1H, br d, J ca.13Hz), 1.82 (1H, d, J 13.7Hz), 1.77 (1H, m), 1.60 (2H, overlapping, J 13.5 and 4.4Hz), 1.52 (1H, m), 1.42 (1H, m), 1.18 (3H, d, J 5.9Hz), 1.13 (6H, s), 1.09 (3H, d, J 6.0Hz), 0.92 (3H, d, J 6.6Hz), 0.89 (3H, d, J 6.6Hz) ppm. Acid Hydrolysis (6MHCl/110/18hrs/N2/sealed tube) gives aspartic acid and N-methyl leucine. Physical and spectral data on MM 47756: FAB-Ms (thioglycerol/glycerol) MH+ 1523+-1 Molecular Weight: 1522 Molecular Formula: C73H90N10O26 1H NMR in DMSO d6 at 353K, Tetramethylsilane as internal standard. Inter alia 7.61 (2H, d, J ca.8.0Hz), 7.4 - 7.2 (3H, overlapping m), 7.13 (1H, dd, J 8.0 and 2.0Hz), 7.10 (1H, d, J 2.0 Hz), 7.07 (1H, dd, J 8.0 and 2.0Hz), 6.97 (1H, dd, J 8.0 and 2.0Hz), 6.76 (1H, dd, J 8.5 and 2.0Hz), 6.68 (1H, d, J 8.5Hz), 6.40 (1H, d, J 2.2Hz), 6.35 (1H, d, J 2.2Hz) ppm. |
| The following compounds can be prepared in a similar way: (S)-Z-N-Methylalanine; (R)-Z-N-Methylalanine; (+/-)-Z-N-Methylalanine; (S)-Z-N-Methylleucine; (R)-Z-N-Methylleucine; (+/-)-Z-N-Methylleucine; Z-N-Methylglycine; ... |

[ 3060-46-6 ]
[ 3060-46-6 ]

[ 3060-46-6 ]| Yield | Reaction Conditions | Operation in experiment |
|---|---|---|
| 100% | In hydrogenchloride; methanol; | a) <strong>[3060-46-6]N-methyl-L-leucine</strong> methyl ester <strong>[3060-46-6]N-methyl-L-leucine</strong> (1.3 g, 8.95 mmol) was dissolved in 4M HCl, 1,4-dioxane (10 mL) and methanol (10 mL). The solution was stirred overnight at room temperature, then concentrated to afford the title compound as a white solid (100%). MS (ESI): 160.0 (M+H)+. |
| Yield | Reaction Conditions | Operation in experiment |
|---|---|---|
| 19.41 g (94%) | With potassium hydroxide; In 1,4-dioxane; water; | Step 1: The preparation of (S)-2-(4-tert-butylbenzyl-methyl-amino)-4-methyl-pentanoic acid (IIc) STR30 Step i: (S)-4-Methyl-2-methylamino-pentanoic acid (15 g, 103 mmol) was dissolved in dioxane (100 mL), cooled to 0 C., then treated with H2 SO4 (10 mL) and isobutylene (100 mL). The mixture was stirred and allowed to come to room temperature over 1 hour. The reaction was vented and poured into a rapidly stirred mixture of KOH (20.7 g) in water, ice, and ether. The solution was filtered, and more ether was added. The organic layer was dried over Na2 SO4 and concentrated to give 19.41 g (94%) of (S)4-methyl-2-methylamino-pentanoic acid tert-butyl ester. MS: 202 (M+1 for C11 H23 N1 O2); TLC SiO2, Rf 0.52 (10% MeOH/CH2 Cl2). |